Default company panoramic image
Logo

SOM Biotech SL

We discover, develop, patent and license new indications of drugs. 1 product licensed in US, 1 product in Phase 2a, 20 new projects and 3 co-developments.

  • Stage $1M in TTM Revenue
  • Industry Biotechnology
  • Location Barcelona, Spain
  • Currency EUR
  • Founded December 2009
  • Employees 7
  • Incorporation Type LLC
  • Website sombiotech.com

Company Summary

Founded in 2009, SOM develops new applications of already know drugs, by using mainly its proprietary in-silico platform. We file international patents and develop the compound to clinical proof of concept. Repurposing drugs is going to be a business of more than $30Bill sales in 2020. Our business model is based on up-front, milestones and royalty payments. One product has being licensed to a US company and another one is starting Phase 2.

Team

  • Default avatar
    Oscar Huertas
    Drug Discovery Manager

    Oscar joined SOM in 2012. He holds a degree in Chemistry from the University of Barcelona and a degree in Biochemistry from the University Autonoma de Barcelona, post-graduate degree in Computational Chemistry. He worked 3 years in Intelligent Pharma as Research Scientist developing projects of computational chemistry in different areas. He is responsible for the company drug discovery computerized system.

  • Rinsa
    Chief Executive Officer

    He graduated in Medicine and Surgery, PhD Cum-Laude in Clinical Neurology, MBA from ESADE, PDG from IESE and has completed several courses in biotechnology in the Harvard Business School. He held senior positions for over 22 years in multinational pharmaceutical companies such as Parke-Davis (Pfizer), UCB Pharma, Uriach Group (Palau Pharma) and ISDIN (Esteve Group).

  • Default avatar
    Núria Reig
    Chief Scientific Officer

    PhD in Biochemistry and Molecular Biology from the UB, cum laude and Special Award for her promotion. She worked 6 years at the Ecole Polytechnique Fédérale de Lausanne (Switzerland), where she shared 50% of her time at Yale University (CT, USA) in research areas related to bacterial pathogenesis and immunology. During 2 years she worked at Xigen SA, a Swiss biotechnology company specialized in inflammation, with the position of Senior Scientist

  • Default avatar
    Santiago Esteva
    Business Development Manager

    Santiago joined SOM in January 2013. He holds a PhD in Biology from the University of Barcelona, cum laude and a Master in Experimental Biology . He also attended a Master in Pharmaceutical Marketing and has worked as researcher at the Biological School for five years and six more years in a clinical CRO (Pivotal) as Regional Office Manager.

  • Default avatar
    Raj Airey
    Chief Strategy Officer

    He brings more than 30 years of experience in the pharmaceutical industry of which 17 were with Pfizer - including eight years in Country President roles in EU. He was also CEO of Baxter India. He is founding partner of HealthStart Pte Ltd as well as Wizzcare Home Health Solutions.

  • Default avatar
    Joaquim Trias
    Chief Scientific Advisor & Member of the Board

    Located in San Francisco has participated in more than 7 biotech companies as either co-founder or board member in the last 30 years.

  • 0ede5395 0e4b 4852 93db 6690228cf80e
    R&D Manager

    Solid experience in biotech companies for more than 10 years as senior scientist and also in clinical research coordination in hospitals in Italy.

  • 7ff8c7fe a5fc 44da aad1 d53a2e9bb601
    Junior Scientist

    Aileen is a Pharmacist by training and holds a Degree in Molecular Biotechnology from the University of Barcelona. She performed her Master Internship at SOM Biotech giving support to the R&D Unit. She finally joined the company as Junior Scientist in September 2016

  • Default avatar
    Leonard Brandt
    US Strategic Advisor

    Based in Los Angeles (CA), Len was General Partner at Norwest Ventures and has been co-founder of CNS Response Inc, Mill City Venture Consulting Inc, , HDI, Empro Vascular, Micronet Medical, Time Segment Publishing and DermaGenoma Inc. Len is connected to 25 board members in 3 different organizations across 4 different industries.

Advisors

  • Default avatar
    Anna Santaulária (CS Advocats Associats)
    Lawyer
    Unconfirmed
    Default avatar
    Mónica Español (Ribe Salat)
    Accountant
    Unconfirmed
    Default avatar
    Hermann Mucke IP Advisor. Austria.
    Unconfirmed

Previous Investors

  • Default avatar
    1 founder (R. Insa)
    Unconfirmed
    Default avatar
    12 locan business angels and 3 family offices
    Unconfirmed
    Default avatar
    20 international business angels
    Unconfirmed